Drug Search Results
More Filters [+]

Trafermin

Alternative Names: trafermin
Latest Update: 2023-05-24
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: FGFR Agonist

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Topical

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Japan

Approved Indications: None

Known Adverse Events: None

Company: Kaken Pharmaceutical Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Trafermin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Diabetic Foot|Periodontal Attachment Loss|Alveolar Bone Loss|Periodontitis

Phase 2: Periodontitis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

The TRAfermin in Neuropathic diabetic foot ulcer Study - southern Europe. The TRANS-North study

P3

Completed

Diabetic Foot

2013-02-06

The TRAfermin in Neuropathic diabetic foot ulcer Study - northern Europe. The TRANS-North study

P3

Terminated

Diabetic Foot

2012-09-30

TRANS-North

P3

Completed

Diabetic Foot

2012-05-01

TRANS-South

P3

Completed

Diabetic Foot

2012-03-01

Recent News Events